Target intelligence / Profile preview

Transient receptor potential vanilloid 6 channel (TRPV6)

Target
TRPV6
Molecular classification
Ion channel, Transient receptor potential (TRP) channel, Vanilloid subfamily member
01

Overview

Transient receptor potential vanilloid 6 channel (TRPV6) is a highly calcium-selective ion channel of the TRP family, primarily expressed in epithelial tissues (such as intestine, kidney, placenta, exocrine glands, and reproductive organs) where it mediates transcellular calcium uptake[2][4][5]. Functionally, it forms a tetrameric channel that permits calcium influx in response to physiological demand, regulated by factors including intracellular calcium, calmodulin, and lipid interactions[1]. It is essential for systemic calcium balance, bone mineralization, and reproductive health. TRPV6 is implicated in numerous pathologies, most notably cancer—where it is overexpressed in aggressive tumors—and inherited disorders of calcium transport[5]. Pharmacological inhibition of TRPV6 is under exploration for anticancer therapy, but may pose risks related to fundamental calcium homeostasis[1][5][7].

Other names
TRPV6ECaC2 (epithelial calcium channel 2)CaT1 (calcium transport protein 1)CatL (calcium channel, epithelial, involved in absorption)
02

Mechanism of action

Channel blockade by small molecules (e.g., 2-APB, ruthenium red, PCHPDs, econazole) leads to inhibition of calcium influx[3][7]. Competitive antagonism with endogenous regulators (e.g., calmodulin-mediated inactivation by calcium binding)[1]. Allosteric modulation via binding at S1–S4 transmembrane bundle or selectivity filter[3][7].

03

Biological functions

Calcium ion transportSignal transductionCellular calcium absorptionRegulation of epithelial calcium uptake
04

Disease associations

CancerChronic pancreatitisMaternal-fetal calcium transport disordersKidney stone formationReproductive disorders (e.g., male infertility)Bone density defects (osteoporosis-like phenotypes)
05

Safety considerations

Targeting may disrupt systemic calcium homeostasis, risking hypocalcemia or hypercalcemia[5].Blockade may affect bone health, fertility, or normal epithelial function[5].Interference with vitamin D-regulated pathways could trigger endocrine/metabolic side effects[5].
06

Interacting drugs

2-aminoethoxydiphenyl borate (2-APB)

4 more in the full profile.

07

Biomarkers

Overexpression in certain cancers (e.g., prostate, breast, colon, pancreatic cancers) as a marker of tumor aggressiveness[5].Elevated TRPV6 mRNA/protein levels indicate dysregulated calcium transport in tissues[5].

Beyond the preview

Go deeper on Transient receptor potential vanilloid 6 channel (TRPV6).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Transient receptor potential vanilloid 6 channel (TRPV6).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call